VPC
VERA icon

Vestal Point Capital’s Vera Therapeutics VERA Stock Holding History

Vestal Point Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,368,159
Closed -$55M – 95
2026
Q1 		$55M Buy
1,368,159
+818,159
+149% +$35.2M 1.54% 22
2025
Q4 		$27.9M Sell
550,000
-210,000
-28% -$7.46M 0.95% 32
2025
Q3 		$22.1M Sell
760,000
-2,340,000
-75% -$54.1M 1% 38
2025
Q2 		$73M Buy
3,100,000
+600,000
+24% +$13.5M 3.85% 5
2025
Q1 		$60M Buy
2,500,000
+1,425,000
+133% +$45.8M 4.29% 5
2024
Q4 		$45.5M Buy
+1,075,000
New +$47.6M 2.7% 12

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vestal Point Capital's VERA Position: Q2 2026 in Review

Vestal Point Capital sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 1,368,159 shares — an estimated $55M sold.

Vestal Point Capital first reported a position in VERA in Q4 2024 and held it in 6 quarters. The position peaked at $73M in Q2 2025. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Vestal Point Capital reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 1,368,159 Vera Therapeutics shares in Q2 2026, an estimated $55M.
  • Vestal Point Capital first reported a position in Vera Therapeutics in Q4 2024 and held it in 6 quarters.
  • Vestal Point Capital's Vera Therapeutics position peaked at $73M in Q2 2025.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.